神経変性疾患治療薬の世界市場2018-2022

◆英語タイトル:Global Neurodegenerative Diseases Therapeutics Market 2018 -2022
◆商品コード:IRTNTR23810
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月17日
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、神経変性疾患治療薬の世界市場について調査・分析し、市場概要、市場環境、神経変性疾患治療薬市場規模、疾患別(多発性硬化症、その他、アルツハイマー病、パーキンソン病、ハンチントン病)分析、薬剤クラス別分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・神経変性疾患治療薬の世界市場概要
・神経変性疾患治療薬の世界市場環境
・神経変性疾患治療薬の世界市場動向
・神経変性疾患治療薬の世界市場規模
・神経変性疾患治療薬の世界市場:業界構造分析
・神経変性疾患治療薬の世界市場:疾患別(多発性硬化症、その他、アルツハイマー病、パーキンソン病、ハンチントン病)
・神経変性疾患治療薬の世界市場:薬剤クラス別
・神経変性疾患治療薬の世界市場:地域別市場規模・分析
・神経変性疾患治療薬の北米市場規模・予測
・神経変性疾患治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・神経変性疾患治療薬のアジア太平洋市場規模・予測
・神経変性疾患治療薬の主要国分析
・神経変性疾患治療薬の世界市場:意思決定フレームワーク
・神経変性疾患治療薬の世界市場:成長要因、課題
・神経変性疾患治療薬の世界市場:競争環境
・神経変性疾患治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、ALLERGAN、Biogen、Novartis、and Teva Pharmaceuticalなどです。
【レポートの概要】

About this market
Increase in aging population to drive growth in the market. The aging population has been increasing globally with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn increased the risk of developing neurological disorders such as Alzheimer’s and Parkinson’s disease. Technavio’s analysts have predicted that the neurodegenerative diseases therapeutics market will register a CAGR of almost 8% by 2022.
Market Overview
Availability of highly sensitive diagnostic modalities
The development of advanced diagnostic modalities to identify disease manifestation at its earliest stages facilitates early treatment decisions, thereby easing disease burden. Neuroimaging is one of the methods for the early diagnosis of neurodegenerative diseases.
High failure rate of neurodegenerative drugs in clinical trials
There has been a continuous development of drugs for the treatment of neurodegenerative diseases. However, there is reportedly a high failure rate of neurodegenerative drugs in clinical trials.
For the detailed list of factors that will drive and challenge the growth of the neurodegenerative diseases therapeutics market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Teva Pharmaceutical the competitive environment is quite intense. Factors such as the increase in aging population and the availability of highly sensitive diagnostic modalities, will provide considerable growth opportunities to neurodegenerative diseases therapeutics manufactures. ALLERGAN, Biogen, Novartis, and Teva Pharmaceutical are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY INDICATION
• Segmentation by indication
• Comparison by indication
• Multiple sclerosis – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Alzheimer’s disease – Market size and forecast 2017-2022
• Parkinson’s disease – Market size and forecast 2017-2022
• Huntington’s disease – Market size and forecast 2017-2022
• Market opportunity by indication
PART 09: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• Biogen
• Novartis
• Teva Pharmaceutical
PART 17: APPENDIX
• List of abbreviations

Exhibit 01: Parent market
Exhibit 02: Global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs under Phase III development
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global neurodegenerative diseases therapeutics market – Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global neurodegenerative diseases therapeutics market – Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Global neurodegenerative diseases therapeutics market by indication – Market share 2017-2022 (%)
Exhibit 20: Comparison by indication
Exhibit 21: Global neurodegenerative diseases therapeutics market by multiple sclerosis – Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Global neurodegenerative diseases therapeutics market by multiple sclerosis – Year over year growth 2018-2022 (%)
Exhibit 23: Global neurodegenerative diseases therapeutics market by others – Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Global neurodegenerative diseases therapeutics market by others – Year over year growth 2018-2022 (%)
Exhibit 25: Global neurodegenerative diseases therapeutics market by Alzheimer’s disease – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global neurodegenerative diseases therapeutics market by Alzheimer’s disease – Year over year growth 2018-2022 (%)
Exhibit 27: Global neurodegenerative diseases therapeutics market by Parkinson’s disease – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global neurodegenerative diseases therapeutics market by Parkinson’s disease – Year over year growth 2018-2022 (%)
Exhibit 29: Global neurodegenerative diseases therapeutics market by Huntington’s disease – Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Global neurodegenerative diseases therapeutics market by Huntington’s disease – Year over year growth 2018-2022 (%)
Exhibit 31: Market opportunity by indication
Exhibit 32: Customer landscape
Exhibit 33: Global neurodegenerative diseases therapeutics market by region – Market share 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: Neurodegenerative diseases therapeutics market in Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 36: Neurodegenerative diseases therapeutics market in Americas – Year over year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in Americas
Exhibit 38: Neurodegenerative diseases therapeutics market in EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 39: Neurodegenerative diseases therapeutics market in EMEA – Year over year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in EMEA
Exhibit 41: Neurodegenerative diseases therapeutics market in APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 42: Neurodegenerative diseases therapeutics market in APAC – Year over year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Market opportunity
Exhibit 45: Late-stage pipeline for different neurogenerative diseases during 2017-2018
Exhibit 46: Some patent expiries of neurodegenerative diseases in US
Exhibit 47: Some drug failures for neurodegenerative diseases in clinical trials in 2017-2018
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Vendor overview
Exhibit 54: ALLERGAN – Business segments
Exhibit 55: ALLERGAN – Organizational developments
Exhibit 56: ALLERGAN – Geographic focus
Exhibit 57: ALLERGAN – Segment focus
Exhibit 58: ALLERGAN – Key offerings
Exhibit 59: Vendor overview
Exhibit 60: Biogen – Business segments
Exhibit 61: Biogen – Organizational developments
Exhibit 62: Biogen – Geographic focus
Exhibit 63: Biogen – Key offerings
Exhibit 64: Vendor overview
Exhibit 65: Novartis – Business segments
Exhibit 66: Novartis – Organizational developments
Exhibit 67: Novartis – Geographic focus
Exhibit 68: Novartis – Segment focus
Exhibit 69: Novartis – Key offerings
Exhibit 70: Vendor overview
Exhibit 71: Teva Pharmaceutical – Business segments
Exhibit 72: Teva Pharmaceutical – Organizational developments
Exhibit 73: Teva Pharmaceutical – Geographic focus
Exhibit 74: Teva Pharmaceutical – Segment focus
Exhibit 75: Teva Pharmaceutical – Key offerings




【掲載企業】

ALLERGAN、Biogen、Novartis、and Teva Pharmaceutical

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経変性疾患治療薬の世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆